|Over a week ago|
Paulson adds Kirkland Lake, exits Caesars in Q1 » 16:3705/1505/15/20
KL, NAV, AEM, CZR, LOGM, TIF, TECD, QEP, ENDP, NG, GLD, DISCA, AU, TSU, PCG, BHC, HZNP, TAK
John Paulson's Paulson & Co. disclosed in an SEC filing its holdings as of March 31, 2020. The fund's two new buys during the first quarter included, by size of position, Kirkland Lake (KL) and Navistar (NAV). Paulson exited six holdings during the quarter, including by size of previous position Agnico Eagle Mines (AEM), Caesars (CZR), and LogMeIn (LOGM). The fund increased its stake in five holdings, including by size of previous position Tiffany (TIF), Tech Data (TECD), QEP Resources (QEP), Endo (ENDP), and Novagold (NG). Paulson reduced its stake in nine holdings, including by size of previous position SPDR Gold Shares (GLD), Discovery (DISCA), AngloGold Ashanti (AU), Tim Participacoes (TSU), and Pretium Resources (PVG). The fund's top holdings as of March 31, in order of size, were Bausch Health (BHC), SPDR Gold Shares, Horizon Therapeutics (HZNP), Takeda Pharmaceutical (TAK), and AngloGold Ashanti.
Endo up 6% after reporting Q1 results 08:2505/0705/07/20
Endo reports Q1 International Pharmaceuticals segment revenue $29M » 08:2405/0705/07/20
Q1 International Pharmaceuticals segment revenues of $29 million were comparable to the same period in the prior year.
Endo reports Q1 Generic Pharmaceuticals revenue $251M vs. $219M last year » 08:2405/0705/07/20
Q1 Generic Pharmaceuticals segment revenues were $251 million, an increase of 15% compared to $219 million in first-quarter 2019. This increase was primarily attributable to recent product launches and accelerated prescription fulfillment resulting from consumer access concerns related to the COVID-19 pandemic and was partially offset by continued competitive pressure on commoditized generic products. During first-quarter 2020, the Generic Pharmaceuticals segment launched four products.
Endo reports Q1 Sterile Injectables segment revenue $336M vs. $270M last year » 08:2205/0705/07/20
Q1 Sterile Injectables…
Q1 Sterile Injectables segment revenues were $336 million, an increase of 25% compared to $270 million in first-quarter 2019. This increase reflects the strong growth of VASOSTRICT and ADRENALIN resulting primarily from significantly increased sales volume towards the end of the quarter due to higher utilization primarily to treat patients infected with COVID-19, increased channel inventory stocking and price.
Endo reports Q1 Branded Pharmaceuticals segment revenues $204M » 08:2105/0705/07/20
Q1 Branded Pharmaceuticals segment revenues of $204 million were comparable to the same period in the prior year. Continued strong growth in the segment's Specialty Products portfolio was offset by ongoing generic competition in the segment's Established Products portfolio. Specialty Products revenues increased 17% to $134 million in first-quarter 2020 compared to $115 million in first-quarter 2019, primarily driven by the strong performance of XIAFLEX. Sales of XIAFLEX increased 30% to $89 million compared to $69 million in first-quarter 2019, which was primarily attributable to demand growth driven by continued commercial execution and investment in promotional activities as well as inventory stocking in the specialty pharmacy and specialty distributor channels.
Endo reports Q1 adj. EPS 94c, consensus 54c » 06:0705/0705/07/20
Reports Q1 revenue $820M,…
Reports Q1 revenue $820M, consensus $712.85M. "I am proud of the way Endo is responding to the challenges associated with the COVID-19 pandemic. We have taken appropriate steps to protect the health and safety of our nearly 3,200 team members and their families around the globe, to support our communities through monetary and product donations, and to rapidly increase the production and distribution of Endo's critical care products which are administered to patients suffering from COVID-19," said Blaise Coleman, President and CEO at Endo. Mr. Coleman continued, "Our first-quarter 2020 results reflect continued strong underlying performance from our Sterile Injectables segment and the Specialty Products Portfolio of our Branded Pharmaceuticals segment. Our results were significantly augmented by higher patient demand and increased customer inventory purchasing due to the COVID-19 pandemic. Although the future impact on our business from COVID-19 is uncertain, we will continue our commitments to keeping our team members safe, reliably supplying critical medicines to patients in need and investing for long term success."
|Over a month ago|
Fly Intel: Top five analyst initiations » 10:0804/2404/24/20
RDUS, QFIN, AWK, WTRG, SJW, ARW, AVT, TEVA, MNK, ENDP, BHC
Catch up on today's…
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Radius Health (RDUS) initiated with a Hold at Stifel. 2. 360 Finance (QFIN) initiated with an Overweight at Morgan Stanley. 3. American Water (AWK), Essential Utilities (WTRG), and SJW Group (SJW) were initiated with an Outperform at RBC Capital. 4. Arrow Electronics (ARW) was initiated with a Buy at Loop Capital while Avnet (AVT) was initiated with a Hold. 5. Endo (ENDP) and Bausch Health (BHC) were initiated with a Buy at Citi, while Mallinckrodt (MNK) was initiated with a Sell, and Teva (TEVA) was initiated with a Neutral. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
Endo initiated with a Buy at Citi » 06:2504/2404/24/20
Citi analyst Navann Ty…
Citi analyst Navann Ty initiated coverage of Endo International with a Buy rating and $7 price target. The low opioid settlements so far and their rationale may help with Endo's future negotiations, Ty tells investors in a research note. The analyst recommends investors buy the stock for the company's progress in cellulite.
Cantor Fitzgerald biopharma analyst to hold analyst/industry conference call » 10:5503/0903/09/20
ENDP, JNJ, MNK, TEVA
Specialty Pharmaceuticals Analyst Chen and Biopharma Analyst Folkes, along with Ilkiko Mehes, Pharmaceutical Industry Legal Advisor, discuss the opioid liabilities for Johnson & Johnson, Teva Pharma, Endo Pharma, Mallinckrodt and others, as well as a review of Purdue's opioid litigation and the potential for a universal settlement at a luncheon discussion being held in Boston on March 9 at 12 pm.